Article

Fractioned radiotherapy safe and effective for optic nerve sheath meningiomas

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas, according to Silas Wang, MD.

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas, according to Silas Wang, MD.

"Optic nerve sheath meningiomas are rare and constitute only 1.3% of meningiomas," Dr. Wang said at the American Academy of Ophthalmology annual meeting.

Dr. Wang and colleagues from Yale University School of Medicine, New Haven, CT, used primary conformal fractioned radiotherapy (45.00 to 54.00 Gy in 25 to 29 fractions) in 16 patients, 14 of whom were women (average age, 45.1 years). Ninety-four percent of the patients had had vision loss. The mean follow-up was 45 months.

Dr. Wang reported that the visual acuity stabilized in 11 patients and the final visual acuity was 20/20 or better in nine patients. One patient had a progress decline in visual acuity to hand motion vision. There was an improvement of two or more lines of visual acuity in four patients. The visual fields improved by a mean of 3.2 decibels. In addition, the color vision stabilized. The delayed complications of the treatment included dry eye and hormonal changes. The results that Dr. Wang reported are consistent with those of a previous study.

"Conformal fractionated radiotherapy is effective in mild visual acuity loss," he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.